DXV301

(A Phase 3, Open-label, Multi-Center Study to Determine Efficacy and Safety of VISIPAQUE™ (iodixanol) Injection for Use in Intravenous Contrast-Enhanced CT Angiography of Coronary Arteries)

The DXV301 trial is a multi-center trial being conducted at 20 centers in North America. The trial is sponsored by GE Healthcare. The objective of this trial is to evaluate diagnostic performance and safety of iodixanol (VisipaqueTM) for use in intravenous contrast-enhanced CTA of coronary arteries. The targeted population is subjects referred for an elective coronary angiography for various reasons.

Contant Info Principal Investigator: Ronald P. Karlsberg, MD Study Coordinator: : Tracey S. Gerez, BS, MA Contact number: 310.275.9551

Clinical Trials

Congestive Heart Failure

FUSION II

PROCLAIM

RED HF

Heart Failure Devices

PEGASUS CRT

OPTIMIZER III

Acute Coronary Syndrome

Horizons

Triton – TIMI 38

Coronary Artery Disease

Crescendo

Transcendence PCI

TACT

Carotid Artery Disease

CAPTURE 2

CT Projects

DXV406

DXV301